A network model of the gut host-microbe ecosystem in Inflammatory Bowel Disease

炎症性肠病肠道宿主微生物生态系统的网络模型

基本信息

项目摘要

DESCRIPTION (provided by applicant): Recent studies highlight a crucial role for gut mucosal immunity in both gut-proximal autoimmune diseases (Inflammatory Bowel Disease (IBD)) and in those involving extraintestinal compartments (rheumatoid arthritis and multiple sclerosis). The development of autoimmune disease involves the coordination of multiple gut- resident cell types and the gut microbiome. On the host side, immune cells and intestinal epithelium orchestrate gut microbial homeostasis via secretion of effector cytokines, antimicrobial peptides, and other molecules. Microbiota are also important modulators of immune responses, influencing the differentiation and function of immune cell populations. We propose an experimental design that combines IBD-relevant perturbations of host and microbiota. Cell abundance (immune cell and microbiota, Aim 1) and genomic measurements (microbial and host cell transcriptomics, Aim 2) will be combined into an integrated experimental design that will allow us to connect ecological changes in the gut to underlying molecular events in bacteria and host immune cells. We will combine three host perturbations (inhibition of ROR�t, IL-10 and IL- 23) with the introduction of two microbes that induce IBD-relevant phenotypes (Segmented Filamentous Bacteria (SFB) and Helicobacter hepaticus (Hh)) into specific pathogen free mice (mice with "normal" microbiomes). SFB adheres to the small intestinal epithelium and causes the expansion of Th17 cell populations in the lamina propria, influencing colitis, arthritis- and MS-relevant phenotypes. The commensal Hh promotes an anti-inflammatory immune response to limit its own gut colonization and only induces colitis-like pathologies in mouse strains with disrupted immune function. Hh-dependent murine colitis mirrors human IBD, where otherwise harmless gut microbial perturbations lead to chronic intestinal dysbiosis in genetically immune-deficient hosts. SFB and Hh interact with IL-23 and IL-10 signaling pathways (both strongly implicated in IBD pathogenesis). Blockade of IL-23 signaling contributes to the efficacy of IL-12p40 antibody therapy for IBD and genome-wide association studies confirm a central role for IL-23R in colitis. In humans mutations in IL10R are associated with IBD and IL-10 signaling deficiency in mice leads to spontaneous microbiome- dependent colitis upon Hh colonization. Our matrix of host and immune perturbations will allow us to explore distinct complementary IBD-relevant host responses. We will focus on human-relevant mechanisms by combining our results with existing databases of human genetic variations associated with IBD and autoimmune disease to select host genes that can then be further studied in mouse models along with relevant bacteria and their products (the intersection of our host regulatory network and the set of human orthologs with IBD association, Aim 3). Completion of our study will result in a new quantitative understanding of the large network of interactions between the immune system and the microbiome and will identify molecular mechanisms relevant for designing new interventions for human inflammatory bowel disease.
描述(由申请人提供):最近的研究强调了肠道粘膜免疫在肠道近端自身免疫性疾病(炎症性肠病(IBD))和涉及肠外隔室的疾病(类风湿性关节炎和多发性硬化症)中的关键作用。自身免疫性疾病的发展涉及多种肠道驻留细胞类型和肠道微生物组的协调。在宿主方面,免疫细胞和肠上皮通过分泌效应细胞因子、抗微生物肽和其他分子来协调肠道微生物稳态。微生物群也是免疫应答的重要调节剂,影响免疫细胞群体的分化和功能。我们提出了一个实验设计,结合IBD相关的扰动主机和微生物群。细胞丰度(免疫细胞和微生物群,Aim 1)和基因组测量(微生物和宿主细胞转录组学,Aim 2)将结合成一个综合的实验设计,使我们能够将肠道中的生态变化与细菌和宿主免疫细胞中的潜在分子事件联系起来。我们将结合联合收割机三个主机扰动(抑制ROR?t,IL-10和IL- 23)引入两种微生物诱导IBD相关表型(节段丝状细菌(SFB)和肝螺杆菌(Hh))到特定病原体自由小鼠(小鼠与“正常”微生物组)。SFB粘附于小肠上皮并导致固有层中Th 17细胞群的扩张,影响结肠炎、关节炎和MS相关表型。Hh促进抗炎免疫应答以限制其自身的肠道定植,并且仅在免疫功能被破坏的小鼠品系中诱导结肠炎样病理。Hh依赖性小鼠结肠炎反映了人类IBD,其中在遗传免疫缺陷宿主中,原本无害的肠道微生物扰动导致慢性肠道生态失调。SFB和Hh与IL-23和IL-10信号通路相互作用(两者都强烈地涉及IBD发病机制)。IL-23信号传导的阻断有助于IL-12 p40抗体治疗IBD的疗效,全基因组关联研究证实了IL-23 R在结肠炎中的核心作用。在人中,IL 10 R的突变与IBD相关,并且小鼠中的IL-10信号传导缺陷导致在Hh定殖后自发的微生物组依赖性结肠炎。我们的宿主和免疫扰动矩阵将使我们能够探索不同的互补IBD相关宿主反应。我们将通过将我们的结果与现有的与IBD和自身免疫性疾病相关的人类遗传变异数据库相结合,以选择可以在小鼠模型中进一步研究的宿主基因,沿着相关细菌及其产物(我们的宿主调控网络与IBD相关的人类直系同源物集的交叉点,目标3)。我们研究的完成将导致对免疫系统和微生物组之间相互作用的大型网络的新的定量理解,并将确定与设计人类炎症性肠病新干预措施相关的分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD A BONNEAU其他文献

RICHARD A BONNEAU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD A BONNEAU', 18)}}的其他基金

Integrating spatial multi-omics and clinical covariates to identify mechanisms of disease in ALS-FTD
整合空间多组学和临床协变量以确定 ALS-FTD 的疾病机制
  • 批准号:
    10034901
  • 财政年份:
    2020
  • 资助金额:
    $ 63.61万
  • 项目类别:
Modeling Gene Regulatory Networks for Early Cardiopharyngeal Development
早期心咽发育的基因调控网络建模
  • 批准号:
    10478845
  • 财政年份:
    2018
  • 资助金额:
    $ 63.61万
  • 项目类别:
Modeling Gene Regulatory Networks for Early Cardiopharyngeal Development
早期心咽发育的基因调控网络建模
  • 批准号:
    10237291
  • 财政年份:
    2018
  • 资助金额:
    $ 63.61万
  • 项目类别:
A network model of the gut host-microbe ecosystem in Inflammatory Bowel Disease
炎症性肠病肠道宿主微生物生态系统的网络模型
  • 批准号:
    9087224
  • 财政年份:
    2014
  • 资助金额:
    $ 63.61万
  • 项目类别:
A network model of the gut host-microbe ecosystem in Inflammatory Bowel Disease
炎症性肠病肠道宿主微生物生态系统的网络模型
  • 批准号:
    8767160
  • 财政年份:
    2014
  • 资助金额:
    $ 63.61万
  • 项目类别:
HUMAN PROTEOME FOLDING PROJECT (HPF)
人类蛋白质组折叠项目(HPF)
  • 批准号:
    8171349
  • 财政年份:
    2010
  • 资助金额:
    $ 63.61万
  • 项目类别:
Elucidation of the transcriptional network underlying the Th17 lineage program.
阐明 Th17 谱系程序背后的转录网络。
  • 批准号:
    8047317
  • 财政年份:
    2010
  • 资助金额:
    $ 63.61万
  • 项目类别:
HUMAN PROTEOME FOLDING PROJECT (HPF)
人类蛋白质组折叠项目(HPF)
  • 批准号:
    7723735
  • 财政年份:
    2008
  • 资助金额:
    $ 63.61万
  • 项目类别:
HUMAN PROTEOME FOLDING PROJECT (HPF)
人类蛋白质组折叠项目(HPF)
  • 批准号:
    7602084
  • 财政年份:
    2007
  • 资助金额:
    $ 63.61万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 63.61万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 63.61万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 63.61万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 63.61万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 63.61万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 63.61万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 63.61万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 63.61万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 63.61万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 63.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了